2. Search Result
Search Result
Results for "

Fidaxomicin

" in MedChemExpress (MCE) Product Catalog:

5

Inhibitors & Agonists

2

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-17580
    Fidaxomicin
    5+ Cited Publications

    OPT-80; PAR-101

    		 DNA/RNA Synthesis Bacterial Apoptosis Antibiotic Infection
    Fidaxomicin (OPT-80), a macrocyclic antibiotic, is an orally active and potent RNA polymerase inhibitor. Fidaxomicin has a narrow spectrum of antibacterial activity and a good anti-Clostridium difficile activity (MIC90=0.12 μg/mL). Fidaxomicin can be used for Clostridium difficile infection (CDI) research .
    Fidaxomicin
  • HY-17580S
    Fidaxomicin-d7

    		Isotope-Labeled Compounds DNA/RNA Synthesis Bacterial Apoptosis Antibiotic Infection
    Fidaxomicin-d7 (OPT-80-D7) is the deuterium labeled Fidaxomicin. Fidaxomicin (OPT-80), a macrocyclic RNA polymerase inhibitor, has a narrow spectrum of activity. Fidaxomicin selectively eradicates pathogenic Clostridium difficile with minimal disruption to the multiple species of bacteria that make up the normal, healthy intestinal flora .
    Fidaxomicin-d7
  • HY-17580R
    Fidaxomicin (Standard)

    OPT-80 (Standard); PAR-101 (Standard)

    		 Reference Standards DNA/RNA Synthesis Bacterial Apoptosis Antibiotic Infection
    Fidaxomicin (Standard) is the analytical standard of Fidaxomicin. This product is intended for research and analytical applications. Fidaxomicin (OPT-80), a macrocyclic antibiotic, is an orally active and potent RNA polymerase inhibitor. Fidaxomicin has a narrow spectrum of antibacterial activity and a good anti-Clostridium difficile activity (MIC90=0.12 μg/mL). Fidaxomicin can be used for Clostridium difficile infection (CDI) research .
    Fidaxomicin (Standard)
  • HY-138135
    OP-1118

    Fidaxomicin metabolite OP-1118

    		 NF-κB ERK Apoptosis Bacterial Infection
    OP-1118 (Fidaxomicin metabolite OP-1118) is an orally active dual inhibitor of NF-κB and ERK1/2, with low systemic plasma exposure, no accumulation, and primary excretion via feces. By inhibiting the phosphorylation of NF-κB and ERK1/2 and reducing the expression of pro-inflammatory cytokines, OP-1118 exerts significant anti-inflammatory, cytoprotective, anti-apoptotic and antibacterial activities. In Clostridium difficile infection models, OP-1118 effectively blocks toxin-mediated intestinal inflammation, cell rounding, histological damage and apoptosis, and its protective effect can be reversed by PMA (HY-18739) .
    OP-1118
  • HY-116880
    DS-2969b

    		Bacterial DNA/RNA Synthesis Infection
    DS-2969b is an orally active GyrB inhibitor with antibacterial activity. DS-2969b is is active against Clostridium difficile infection (MIC90: 0.06 μg/mL), which is 2-, 16-, and 32-fold lower than those of Fidaxomicin (HY-17580), Metronidazole (HY-B0318), and Vancomycin (HY-B0671), respectively. DS-2969b inhibits the supercoiling activity of C. difficile DNA gyrase. DS-2969b also exhibits activity against other Gram-positive anaerobes, including strict and facultative anaerobes. DS-2969b is safe and well tolerated in preclinical toxicology studies .
    DS-2969b

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: